ColasantiG., SantoroA., SalomoneM., ConteF., SalvadoriM., PostorinoM.Registro Italiano di Dialisi e Trapianto: Report del registro, anno
1998. 41° Congresso della SIN, Taormina, 14-17 Giugno
2000.
2.
GiannattasioM.Emodialisi o peritoneodialisi come terapia di prima scelta
dell'uremia cronica?Giorn It Nefrol2000; 17:
161–9.
3.
KhanI.H., MacLeodA.M.Towards cost-effective dialysis therapy in Europe: the need for a
multi-disciplinary approach. Nephrol Dial
Transplant1997; 12:
2483–5.
4.
ShaldonS., KockK.M., QuellhorstE., LonnemannG., DinarelloC.CAPD is a second class treatment. Contrib
Nephrol1985; 44:
163–5.
5.
LupoA., CancariniG., CatizoneL.Comparison of survaival in CAPD and hemodialysis: a multi-center
study. Adv Peritoneal Dial1992; 8:
136–40.
6.
FentonS.S.A., ScahubellD.E., DesmeulesM., Hemodialysis versus peritoneal dialysis: a comparison of adjusted
mortality rates. Am J Kidney Dis1997; 30:
334–42.
7.
DavisS.G., PhillipsL., GriffithsA.M., RusselL.H.What really happens to people on long-term peritoneal
dialysis?Kidney Int1998; 54:
2207–17.
8.
GokalR., FiguerasM., OllèA., RoviraJ., BadiX.Outcomes in peritoneal dialysis and haemodialysis – a comparative
assessment of survival and quality of life. Nephrol
Dial Transplant1999; 14(Suppl):
S24–30.
9.
US Renal Data System: USRDS 1998
Annual Data Report. The National Institutes of Health,
National Institute of Diabetics and Digestive and Kidney Diseases.
Bethesda, MD, 1998.
10.
SlimgeneyerA., De VecchiA., FallerB.Multicenter study on patient referral to
dialysis. J Am Soc Nephrol (abs)1998; 9: 226A.
LombardiM., SiscaS.Is HCV-infection another reason to opt for peritoneal dialysis in
End-Stage Renal Failure?Nephron (letter)1997; 76: 357.
13.
LombardiM., CerraiT., GeattiS.Results of a national epidemiological investigation on HCV
infection among dialysis patients (Survey by the Italian Branch of
EDTNA/ERCA). J Nephrol1999; 12:
322–27.
14.
De VecchiA.F., DratwaM., WiedemannM.E.Healthcare systems and end-stage renal disease (ESRD) therapies –
an international review: costs and reimbursement/funding of ESRD
therapies. Nephrol Dial Transplant1999; 14(Suppl):
S31–41.
15.
SchenaF.P., BiasioliS., CavagninoA.Rapporto della Commissione Dialisi (SIN).
Giorn It Nefrol1997; 14:
321–38.
16.
LombardiM., ManfridaG.M., CerraiT., DattoloP., SiscaS.Qualità di vita dell'uremico terminale.
Gior It Nefrol1994; 11:
227–32.
17.
DobbieJ.W.Surfactant protein A and lamellar bodies: a homologous secretory
function of peritoneum, synovium, and lung. Perit
Dial Int1996; 16:
574–81.
18.
BiesenW.V., VanholderR.C., VeysNic, DhondtA., LameireN.H.An evaluation of an integrative care approach for end-stage renal
disease patients. J Am Soc Nephrol2000; 11:
116–25.
HorlW.H., de AlvaroF., WilliamsP.F.Healthcare systems and end-stage renal disease (ESRD) therapies –
an international review: access to ESRD treatments.
Nephrol Dial Transplant1999; 14(Suppl):
S10–15.
